News - ThromboGenics, Alcon

Filter

Current filters:

ThromboGenicsAlcon

Popular Filters

ThromboGenics to begin Jetrea study in USA

ThromboGenics to begin Jetrea study in USA

04-03-2014

Belgium-based biopharma firm ThromboGenics will soon initiate a US Phase IV study with Jetrea (ocriplasmin).

AlconBelgiumJetreaOphthalmicsPharmaceuticalResearchThromboGenics

ThromboGenics explores “strategic options” for the company

ThromboGenics explores “strategic options” for the company

24-02-2014

Belgian biotech firm ThromboGenics revealed this morning that it has retained financial advisor Morgan…

AlconBiotechnologyLicensingMergers & AcquisitionsNovartisOphthalmicsThromboGenics

ThromboGenics’ Jetrea gets positive reimbursement opinion in France

ThromboGenics’ Jetrea gets positive reimbursement opinion in France

17-01-2014

Belgian biotech firm ThromboGenics says that the Transparency Commission of the French National Health…

AlconBiotechnologyJetreaNovartisOphthalmicsPricingThromboGenics

Alcon and ThromboGenics launch Jetrea in Canada

21-11-2013

ThromboGenics NV (Euronext Brussels: THR) and its partner Alcon, the ophthalmic unit of Novartis (NOVN:…

AlconBiotechnologyCanadaJetreaMarkets & MarketingOphthalmicsRegulationThromboGenics

Germany’s G-BA confirms benefits of ThromboGenics’ Jetrea for VMT

18-10-2013

Belgian biotech firm ThromboGenics says that the Final Early Benefit Assessment from the German Federal…

AlconBiotechnologyEuropeJetreaNovartisOphthalmicsPricingRegulationThromboGenics

ThromboGenics' Jetrea gets initial NICE recommendation for VMT

12-06-2013

Belgium-based biopharma company ThromboGenics (Euronext Brussels: THR) said this morning (June 12) that…

AlconEuropeJetreaNovartisOphthalmicsPharmaceuticalPricingRegulationThromboGenics

Alcon and ThromboGenics Jetrea launched in Denmark and Sweden

28-05-2013

Belgium's ThromboGenics (Euronext Brussels: THR) says that its partner Alcon, the eye care subsidiary…

AlconEuropeJetreaMarkets & MarketingNovartisOphthalmicsPharmaceuticalThromboGenics

EU approval of Jetrea triggers a 45 million-euro milestone for ThromboGenics from Alcon

18-03-2013

The European Commission has approved Swiss drug major Novartis' (NOVN: VX) Alcon ophthalmic unit's Jetrea…

AlconEuropeFinancialJetreaNovartisOphthalmicsPharmaceuticalRegulationThromboGenics

Ph III trials show Novartis' Jetrea improves vitreomacular traction

17-08-2012

Swiss drug major Novartis (NOVN: VX) that the New England Journal of Medicine (NEJM) this week published…

AlconJetreaNovartisocriplasminOphthalmicsPharmaceuticalResearchThromboGenics

FDA advisory panel backs approval of ThromboGenics' ocriplasmin for VMA

29-07-2012

Belgian biopharmaceutical firm ThromboGenics NV (Euronext Brussels: THR) says that the US Food and Drug…

AlconBiotechnologyNorth AmericaNovartisocriplasminOphthalmicsRegulationThromboGenics

Novartis unit buys rights to ThromboGenics eye drug

16-03-2012

Belgian biopharma company ThromboGenics (Euronext Brussels: THR) revealed this morning that it has entered…

AlconBiotechnologyLicensingNovartisocriplasminOphthalmicsPharmaceuticalThromboGenics

Back to top